Entries tagged "Roche"

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Roche."

12 result(s) displayed (1 - 12 of 16)

Timing risk in Life Technologies deal

China's Ministry of Commerce is seen as a wild card in the clearance for Thermo Fisher's purchase. Continue reading

Posted on May 8, 2013 9:42 AM

Roche "disappointed" by Illumina poison pill

Roche Holding AG on Friday, Jan. 27, professed itself "disappointed," but not surprised, after Illumina Inc. adopted a poison pill to thwart the Swiss pharmaceutical company's $5.7 billion unwanted approach.Illlumina Thursday said it would give investors who hold its shares... Continue reading

Posted on January 27, 2012 8:56 AM

Scenes from the slowdown

M&A activity may have stalled during the first half of the year, but deal lawyers still had plenty to talk about. Continue reading

Posted on August 7, 2009 10:56 AM

Little pharma blues

As the economy foundered, drug industry insiders looked forward to an M&A frenzy. But with a few exceptions, deals occurred only at the top of the food chain. Continue reading

Posted on March 20, 2009 1:48 PM

Merck, Schering play follow the pharma

Damian Ridealgh and other Fried Frank attorneys advised Merck on its deal for Schering. Continue reading

Posted on March 20, 2009 1:44 PM

Risk Arbitrage: March 9, 2009

March 9, 12 and 20 are important days in the M&A world. Continue reading

Posted on March 6, 2009 11:04 AM

Davis Polk, Roche probe Genentech's DNA

Roche and Genentech have a long history. This time around, Davis Polk's John Butler and others take the lead for Roche. Continue reading

Posted on February 20, 2009 3:10 PM

Surprise!

For sheer drama, Roche's hostile, discounted bid for Genentech tops even Pfizer's bid for Wyeth. Continue reading

Posted on February 6, 2009 1:28 PM

Mood enhancers

Drug companies get a warm reception in the debt market these days. Continue reading

Posted on February 6, 2009 1:12 PM

Risk Arbitrage: Feb. 9, 2009

2009 has begun better than it might have on the M&A front. Continue reading

Posted on February 6, 2009 1:00 PM

They need a new drug

Expect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Continue reading

Posted on January 9, 2009 2:10 PM

Beyond flux

Market chaos has effectively stifled most M&A activities. But investment bankers already look ahead to when a kind of dealmaking normalcy prevails. Continue reading

Posted on October 17, 2008 3:33 PM

Movable Type search results powered by Fast Search